Schlagwortarchiv für: Publikationen: Stefaan Van Gool MD. PhD.
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
/in International Publications, IOZK Aktuelles, IOZK VeröffentlichungenMethods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen, Newcastle Disease VirusDendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Aktuelles, IOZK VeröffentlichungenThe Application of Evidence-Based Medicine in Individualized Medicine
/in International Publications, IOZK VeröffentlichungenIndividualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenStefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences
/in Brain Tumors in Children, IOZK Aktuelles, IOZK VeröffentlichungenCounteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK VeröffentlichungenPosterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK VeröffentlichungenSynergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- The Complexity of Malignant Glioma Treatment
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature